U.S. stock futures are falling sharply; Netflix's subscriber growth lags estimates; AbbVie drops takeover deal for Shire; Google to report earnings.
AbbVie's board is recommending stockholders vote against its $55 billion takeover offer for drugmaker Shire after tax changes reduced the financial advantages of the deal.
U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
European markets remain in the red, amid mounting panic about the prospect of a euro-zone recession.
U.S. stock futures are mixed; AbbVie has second thoughts on Shire merger; Qualcomm to buy U.K. chipmaker CSR; Bank of America to report earnings.
Keep these under-$10 biotech stocks on your breakout trading radar.
Facebook CEO Mark Zuckerberg and his wife, Priscilla Chan, are donating $25 million to the CDC Foundation to help address the Ebola epidemic.
TheStreet's Jim Cramer said he does not trust the market right now, given that quality stocks with good earnings results like J&J are moving lower.
By Brian O'Connell
Financial exploitation of patients by home health care workers is a growing problem, and it's up to you to keep a loved one from becoming a victim.
U.S. stock futures inch higher; JPMorgan swings to a third-quarter profit; Google expands its delivery service; Intel to report earnings.
On Tuesday, October 14th three major banks kick off a big week for third quarter earnings reports.
An experimental Canadian-made Ebola vaccine that has shown promise in tests on primates is beginning clinical trials on humans in the U.S.
Health care investors can be divided into two camps with respect to Sarepta: Those who believe eteplirsen is effective against DMD and those who don't.
Stocks fell in midday trading Monday but some stocks are making big moves to the upside including CSX (CSX).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV